Talphera Appoints Joe Todisco to Board of Directors as Part of CorMedix Investment

Talphera, a specialty pharmaceutical company, has appointed Joe Todisco, CEO of CorMedix Inc., to its Board of Directors. Todisco's experience in the pharmaceutical industry and CorMedix's strategic investment in Talphera make him a valuable addition to the Board. Talphera's lead product candidate, Niyad, is a lyophilized formulation of nafamostat being studied as an anticoagulant for the extracorporeal circuit and has received Breakthrough Device Designation status from the FDA.

Talphera, Inc. (NASDAQ: TLPH), a specialty pharmaceutical company, has appointed Joseph Todisco as a Class III director and member of the compensation committee, effective September 12, 2025. Todisco, currently the Chief Executive Officer of CorMedix Inc., brings extensive experience in the pharmaceutical industry to the Talphera board. His appointment follows a strategic investment by CorMedix in Talphera, which includes a securities purchase agreement and a private placement financing deal.

According to a recent SEC filing, Todisco received an initial grant of 6,397 restricted stock units and options to purchase 38,381 shares of Talphera common stock at an exercise price of $1.11 per share. These awards vest in three equal annual installments over a three-year period, contingent on continued board service. Additionally, Talphera plans to enter into a non-employee director indemnification agreement with Todisco Talphera appoints Joseph Todisco to board, grants CorMedix board designation rights^[1].

Todisco's appointment is significant given CorMedix's strategic investment in Talphera. Under the terms of the agreement, CorMedix has the right to designate one Talphera board member as long as it holds at least 25% of the shares purchased in the initial private placement. Furthermore, CorMedix has an exclusive 60-day period to negotiate a potential acquisition of Talphera following the public announcement of key clinical study results for Talphera's Niyad product candidate Talphera appoints Joseph Todisco to board, grants CorMedix board designation rights^[1].

Todisco's appointment also comes at a time when Talphera is navigating market challenges, including supply chain issues impacting the anticoagulation sector. The company reported strategic reductions in operating expenses and shared significant updates on its clinical trials during its Q2 2025 earnings call. Talphera is working towards potentially becoming the first FDA-approved regional anticoagulant for continuous renal replacement therapy (CRRT). Additionally, Talphera has reached 25% enrollment in its NEPHRO CRRT pivotal clinical trial, with 17 patients enrolled out of the 70-patient target Talphera Inc Stock Price, News & Analysis^[2].